Analyst Price Targets — ALVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:24 pm | Glen Santangelo | Barclays | $5.00 | $5.45 | TheFly | Alvotech initiated with an Underweight at Barclays |
| December 3, 2025 11:32 am | — | Morgan Stanley | $10.00 | $4.60 | TheFly | Alvotech price target lowered to $10 from $14 at Morgan Stanley |
| November 18, 2025 2:33 pm | — | UBS | $10.00 | $5.11 | TheFly | Alvotech price target lowered to $10 from $13 at UBS |
| November 4, 2025 1:17 pm | — | Northland Securities | $10.00 | $4.93 | TheFly | Alvotech price target lowered to $10 from $28 at Northland |
| November 4, 2025 9:49 am | Niall Alexander | Deutsche Bank | $8.00 | $5.03 | StreetInsider | Deutsche Bank Downgrades Alvotech SA (ALVO) to Hold |
| October 14, 2025 8:38 am | — | Morgan Stanley | $14.00 | $7.97 | TheFly | Alvotech upgraded to Overweight from Equal Weight at Morgan Stanley |
| May 24, 2024 5:26 am | Balaji Prasad | Barclays | $22.00 | $13.58 | TheFly | Alvotech price target raised to $22 from $20 at Barclays |
| May 21, 2024 2:22 pm | Balaji Prasad | Barclays | $20.00 | $13.76 | StreetInsider | Barclays Reiterates Overweight Rating on Alvotech SA (ALVO) |
| January 29, 2024 3:32 am | Balaji Prasad | Barclays | $17.00 | $15.25 | StreetInsider | Barclays Upgrades Alvotech SA (ALVO) to Overweight |
| July 1, 2022 5:05 am | Emmanuel Papadakis | Deutsche Bank | $10.00 | $8.21 | TheFly | Alvotech initiated with a Hold at Deutsche Bank |
Latest News for ALVO
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe…
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech's candidates in the United States and selected Asian…
Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ALVO.
Senate Trading
No Senate trades found for ALVO.
U.S. House Trading
No House trades found for ALVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.